Kiniksa Pharmaceuticals International, plc
KNSANasdaq
$63.95
↑ +4.6%Jul 17 close · end-of-day
Price
1Y↑ +125.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.3B
Enterprise Value
$4.8B
P/E
70.3
P/S
7.0
P/B
8.7
EV/EBITDA
50.6
PEG
—
FCF Yield
3.1%
Dividend Yield
—
Revenue (TTM)
$754.0M
Net Income (TTM)
$73.1M
Free Cash Flow (TTM)
$164.2M
Gross Margin
—
Operating Margin
12.4%
Net Margin
9.7%
ROE
12.1%
ROIC
46.7%
Debt / Equity
—
Net Cash
$468.1M
Return 1Y
+121.7%
Company profile
Kiniksa Pharmaceuticals, Ltd. focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease. KPL-404 is a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation.
- CEO
- Sanj K. Patel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 220
- Website
- kiniksa.com
Management & directors
- Patel Sanj KCHAIRMAN & CEO
- Paolini JohnCHIEF MEDICAL OFFICER
- Megna Michael RCHIEF ACCOUNTING OFFICER
- Moat RossCHIEF CORP. & COMM. OFFICER
- Ragosa MarkCHIEF FINANCIAL OFFICER
- Tessari EbenCHIEF OPERATING OFFICER
Roles derived from SEC Form 4 filings.
Earnings
KNSA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$214.3M↑ +55.5%
Diluted EPS$0.27↑ +145.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$157.4M | -$156.6M | $9.8M | -$25.2M | -$45.6M | $77.2M |
| Net income | -$161.4M | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
| Diluted EPS | -$2.61 | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
| Operating cash flow | -$136.5M | -$126.3M | $5.8M | $13.3M | $25.7M | $138.0M |
| Free cash flow | -$136.8M | -$126.7M | $5.7M | $13.2M | $25.4M | $136.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Net margin | — | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.6M | $112.2M | $122.5M | $137.8M | $156.8M | $180.9M | $202.1M | $214.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$117,000.00 | -$9.7M | -$19.3M | $13.3M | $20.2M | $24.0M | $19.8M | $29.3M |
| Net income | -$3.9M | -$12.7M | -$8.9M | $8.5M | $17.8M | $18.4M | $14.2M | $22.6M |
| Diluted EPS | -$0.06 | -$0.18 | -$0.11 | $0.11 | $0.23 | $0.23 | $0.18 | $0.27 |
| Operating cash flow | $5.2M | -$2.2M | $18.8M | $22.3M | $28.1M | $33.7M | $53.9M | $50.2M |
| Free cash flow | $5.2M | -$2.2M | $18.6M | $22.2M | $27.9M | $33.0M | $53.3M | $50.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -0.1% | -8.6% | -15.7% | 9.6% | 12.9% | 13.3% | 9.8% | 13.7% |
| Net margin | -3.6% | -11.3% | -7.3% | 6.2% | 11.4% | 10.2% | 7.0% | 10.5% |
Company news
Jul 14, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Patel Sanj K· CHAIRMAN & CEO | C | 900,000 | — | — | filing |
| 2026-05-29 | BAKER BROS. ADVISORS LP | Award | 6,078 | $0.00 | $0.00 | filing |
| 2026-05-29 | BAKER BROS. ADVISORS LP | Award | 6,078 | $0.00 | $0.00 | filing |
| 2026-05-29 | McCain Tracey L | Option exercise | 2,799 | — | — | filing |
| 2026-05-29 | Malley Thomas | Option exercise | 2,799 | — | — | filing |
| 2026-05-29 | Levy Richard S | Option exercise | 2,799 | — | — | filing |
| 2026-05-29 | Cole G Bradley | Option exercise | 2,799 | — | — | filing |
| 2026-05-29 | Quart Barry D | Option exercise | 2,799 | — | — | filing |
| 2026-05-29 | Popovits Kimberly J | Option exercise | 2,799 | — | — | filing |
| 2026-05-01 | Patel Sanj K· CHAIRMAN & CEO | Sale | 48,565 | $54.02 | $2.6M | filing |
| 2026-05-01 | Paolini John· CHIEF MEDICAL OFFICER | Sale | 37,327 | $53.52 | $2.0M | filing |
| 2026-05-01 | Patel Sanj K· CHAIRMAN & CEO | Option exercise | 48,565 | $30.93 | $1.5M | filing |
| 2026-05-01 | Paolini John· CHIEF MEDICAL OFFICER | Sale | 21,097 | $54.04 | $1.1M | filing |
| 2026-05-01 | Paolini John· CHIEF MEDICAL OFFICER | Option exercise | 58,424 | $10.36 | $605,272.64 | filing |
| 2026-04-30 | Patel Sanj K· CHAIRMAN & CEO | Sale | 2,141 | $54.01 | $115,635.41 | filing |
| 2026-04-30 | Patel Sanj K· CHAIRMAN & CEO | Option exercise | 2,141 | $30.93 | $66,221.13 | filing |
| 2026-04-29 | Patel Sanj K· CHAIRMAN & CEO | Sale | 22,544 | $54.01 | $1.2M | filing |
| 2026-04-29 | Patel Sanj K· CHAIRMAN & CEO | Option exercise | 22,544 | $30.93 | $697,285.92 | filing |
| 2026-04-28 | Patel Sanj K· CHAIRMAN & CEO | Sale | 243,596 | $52.02 | $12.7M | filing |
| 2026-04-28 | Patel Sanj K· CHAIRMAN & CEO | Sale | 113,673 | $51.47 | $5.9M | filing |
| 2026-04-28 | Patel Sanj K· CHAIRMAN & CEO | Option exercise | 431,904 | $10.36 | $4.5M | filing |
| 2026-04-28 | Patel Sanj K· CHAIRMAN & CEO | Sale | 74,635 | $50.43 | $3.8M | filing |
| 2026-04-28 | Patel Sanj K· CHAIRMAN & CEO | Sale | 51,750 | $54.02 | $2.8M | filing |
| 2026-04-28 | Patel Sanj K· CHAIRMAN & CEO | Option exercise | 51,750 | $30.93 | $1.6M | filing |
| 2026-04-28 | Quart Barry D | Sale | 13,099 | $50.10 | $656,259.90 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.